Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
70
RGC Quote, Financials, Valuation and Earnings
Last price:
$41.51
Seasonality move
:
69.73%
Day range:
$35.29 - $54.90
52-week range:
$0.09 - $83.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
989.66x
Volume:
3.2M
Avg. volume:
483.7K
1-year change:
42447.71%
Market cap:
$26.1B
Revenue:
--
EPS (TTM):
-$0.33
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | -- | -- | $22.38 |
|
HKPD
Cellyan Biotechnology Ltd.
|
-- | -- | -- | -- | -- |
|
PRE
Prenetics Global Ltd.
|
$38.3M | -- | 265.18% | -- | $26.00 |
|
SBHMY
Sino Biopharmaceutical Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RGC
Regencell Bioscience Holdings Ltd.
|
$52.88 | -- | $26.1B | -- | $0.00 | 0% | -- |
|
HCM
HUTCHMED (China) Ltd.
|
$14.87 | $22.38 | $2.6B | 4.92x | $0.00 | 0% | 4.30x |
|
HKPD
Cellyan Biotechnology Ltd.
|
$0.82 | -- | $9M | 8.18x | $0.00 | 0% | 0.75x |
|
PRE
Prenetics Global Ltd.
|
$16.49 | $26.00 | $277.5M | -- | $0.00 | 0% | 3.21x |
|
SBHMY
Sino Biopharmaceutical Ltd.
|
$18.22 | -- | $16.3B | 31.84x | $0.13 | 1.26% | 3.87x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | 18.151 | -- | -- |
|
HCM
HUTCHMED (China) Ltd.
|
7.07% | 0.158 | -- | 4.41x |
|
HKPD
Cellyan Biotechnology Ltd.
|
-- | 0.000 | -- | -- |
|
PRE
Prenetics Global Ltd.
|
1.29% | 5.284 | 1.18% | 1.01x |
|
SBHMY
Sino Biopharmaceutical Ltd.
|
23.1% | -0.664 | -- | 1.14x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | 46.32% | 50.64% | -- | -- |
|
HKPD
Cellyan Biotechnology Ltd.
|
-- | -- | -- | -- | -- | -- |
|
PRE
Prenetics Global Ltd.
|
$14M | -$6.6M | -26.04% | -26.74% | -27.85% | -- |
|
SBHMY
Sino Biopharmaceutical Ltd.
|
-- | -- | 6.83% | 8.57% | -- | -- |
Regencell Bioscience Holdings Ltd. vs. Competitors
-
Which has Higher Returns RGC or HCM?
HUTCHMED (China) Ltd. has a net margin of -- compared to Regencell Bioscience Holdings Ltd.'s net margin of --. Regencell Bioscience Holdings Ltd.'s return on equity of -- beat HUTCHMED (China) Ltd.'s return on equity of 50.64%.
Company Gross Margin Earnings Per Share Invested Capital RGCRegencell Bioscience Holdings Ltd.-- -- -- HCMHUTCHMED (China) Ltd.-- -- $1.3B -
What do Analysts Say About RGC or HCM?
Regencell Bioscience Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand HUTCHMED (China) Ltd. has an analysts' consensus of $22.38 which suggests that it could grow by 52.69%. Given that HUTCHMED (China) Ltd. has higher upside potential than Regencell Bioscience Holdings Ltd., analysts believe HUTCHMED (China) Ltd. is more attractive than Regencell Bioscience Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RGCRegencell Bioscience Holdings Ltd.0 0 0 HCMHUTCHMED (China) Ltd.9 2 1 -
Is RGC or HCM More Risky?
Regencell Bioscience Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison HUTCHMED (China) Ltd. has a beta of 0.418, suggesting its less volatile than the S&P 500 by 58.206%.
-
Which is a Better Dividend Stock RGC or HCM?
Regencell Bioscience Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HUTCHMED (China) Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regencell Bioscience Holdings Ltd. pays -- of its earnings as a dividend. HUTCHMED (China) Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RGC or HCM?
Regencell Bioscience Holdings Ltd. quarterly revenues are --, which are smaller than HUTCHMED (China) Ltd. quarterly revenues of --. Regencell Bioscience Holdings Ltd.'s net income of -- is lower than HUTCHMED (China) Ltd.'s net income of --. Notably, Regencell Bioscience Holdings Ltd.'s price-to-earnings ratio is -- while HUTCHMED (China) Ltd.'s PE ratio is 4.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regencell Bioscience Holdings Ltd. is -- versus 4.30x for HUTCHMED (China) Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGCRegencell Bioscience Holdings Ltd.-- -- -- -- HCMHUTCHMED (China) Ltd.4.30x 4.92x -- --
-
Which has Higher Returns RGC or HKPD?
Cellyan Biotechnology Ltd. has a net margin of -- compared to Regencell Bioscience Holdings Ltd.'s net margin of --. Regencell Bioscience Holdings Ltd.'s return on equity of -- beat Cellyan Biotechnology Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RGCRegencell Bioscience Holdings Ltd.-- -- -- HKPDCellyan Biotechnology Ltd.-- -- -- -
What do Analysts Say About RGC or HKPD?
Regencell Bioscience Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Cellyan Biotechnology Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Regencell Bioscience Holdings Ltd. has higher upside potential than Cellyan Biotechnology Ltd., analysts believe Regencell Bioscience Holdings Ltd. is more attractive than Cellyan Biotechnology Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RGCRegencell Bioscience Holdings Ltd.0 0 0 HKPDCellyan Biotechnology Ltd.0 0 0 -
Is RGC or HKPD More Risky?
Regencell Bioscience Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cellyan Biotechnology Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RGC or HKPD?
Regencell Bioscience Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellyan Biotechnology Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regencell Bioscience Holdings Ltd. pays -- of its earnings as a dividend. Cellyan Biotechnology Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RGC or HKPD?
Regencell Bioscience Holdings Ltd. quarterly revenues are --, which are smaller than Cellyan Biotechnology Ltd. quarterly revenues of --. Regencell Bioscience Holdings Ltd.'s net income of -- is lower than Cellyan Biotechnology Ltd.'s net income of --. Notably, Regencell Bioscience Holdings Ltd.'s price-to-earnings ratio is -- while Cellyan Biotechnology Ltd.'s PE ratio is 8.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regencell Bioscience Holdings Ltd. is -- versus 0.75x for Cellyan Biotechnology Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGCRegencell Bioscience Holdings Ltd.-- -- -- -- HKPDCellyan Biotechnology Ltd.0.75x 8.18x -- --
-
Which has Higher Returns RGC or PRE?
Prenetics Global Ltd. has a net margin of -- compared to Regencell Bioscience Holdings Ltd.'s net margin of -28.82%. Regencell Bioscience Holdings Ltd.'s return on equity of -- beat Prenetics Global Ltd.'s return on equity of -26.74%.
Company Gross Margin Earnings Per Share Invested Capital RGCRegencell Bioscience Holdings Ltd.-- -- -- PREPrenetics Global Ltd.59.54% -$0.53 $163.3M -
What do Analysts Say About RGC or PRE?
Regencell Bioscience Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Prenetics Global Ltd. has an analysts' consensus of $26.00 which suggests that it could grow by 87.99%. Given that Prenetics Global Ltd. has higher upside potential than Regencell Bioscience Holdings Ltd., analysts believe Prenetics Global Ltd. is more attractive than Regencell Bioscience Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RGCRegencell Bioscience Holdings Ltd.0 0 0 PREPrenetics Global Ltd.1 0 0 -
Is RGC or PRE More Risky?
Regencell Bioscience Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Prenetics Global Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RGC or PRE?
Regencell Bioscience Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prenetics Global Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regencell Bioscience Holdings Ltd. pays -- of its earnings as a dividend. Prenetics Global Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RGC or PRE?
Regencell Bioscience Holdings Ltd. quarterly revenues are --, which are smaller than Prenetics Global Ltd. quarterly revenues of $23.6M. Regencell Bioscience Holdings Ltd.'s net income of -- is lower than Prenetics Global Ltd.'s net income of -$6.8M. Notably, Regencell Bioscience Holdings Ltd.'s price-to-earnings ratio is -- while Prenetics Global Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regencell Bioscience Holdings Ltd. is -- versus 3.21x for Prenetics Global Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGCRegencell Bioscience Holdings Ltd.-- -- -- -- PREPrenetics Global Ltd.3.21x -- $23.6M -$6.8M
-
Which has Higher Returns RGC or SBHMY?
Sino Biopharmaceutical Ltd. has a net margin of -- compared to Regencell Bioscience Holdings Ltd.'s net margin of --. Regencell Bioscience Holdings Ltd.'s return on equity of -- beat Sino Biopharmaceutical Ltd.'s return on equity of 8.57%.
Company Gross Margin Earnings Per Share Invested Capital RGCRegencell Bioscience Holdings Ltd.-- -- -- SBHMYSino Biopharmaceutical Ltd.-- -- $7.2B -
What do Analysts Say About RGC or SBHMY?
Regencell Bioscience Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sino Biopharmaceutical Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Regencell Bioscience Holdings Ltd. has higher upside potential than Sino Biopharmaceutical Ltd., analysts believe Regencell Bioscience Holdings Ltd. is more attractive than Sino Biopharmaceutical Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RGCRegencell Bioscience Holdings Ltd.0 0 0 SBHMYSino Biopharmaceutical Ltd.0 0 0 -
Is RGC or SBHMY More Risky?
Regencell Bioscience Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sino Biopharmaceutical Ltd. has a beta of 0.590, suggesting its less volatile than the S&P 500 by 40.969%.
-
Which is a Better Dividend Stock RGC or SBHMY?
Regencell Bioscience Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sino Biopharmaceutical Ltd. offers a yield of 1.26% to investors and pays a quarterly dividend of $0.13 per share. Regencell Bioscience Holdings Ltd. pays -- of its earnings as a dividend. Sino Biopharmaceutical Ltd. pays out 55.99% of its earnings as a dividend. Sino Biopharmaceutical Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RGC or SBHMY?
Regencell Bioscience Holdings Ltd. quarterly revenues are --, which are smaller than Sino Biopharmaceutical Ltd. quarterly revenues of --. Regencell Bioscience Holdings Ltd.'s net income of -- is lower than Sino Biopharmaceutical Ltd.'s net income of --. Notably, Regencell Bioscience Holdings Ltd.'s price-to-earnings ratio is -- while Sino Biopharmaceutical Ltd.'s PE ratio is 31.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regencell Bioscience Holdings Ltd. is -- versus 3.87x for Sino Biopharmaceutical Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGCRegencell Bioscience Holdings Ltd.-- -- -- -- SBHMYSino Biopharmaceutical Ltd.3.87x 31.84x -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
70
RGC alert for Jan 8
Regencell Bioscience Holdings Ltd. [RGC] is down 21.5% over the past day.
Buy
64
RVMD alert for Jan 8
Revolution Medicines, Inc. [RVMD] is up 4.61% over the past day.
Sell
38
CRNX alert for Jan 8
Crinetics Pharmaceuticals, Inc. [CRNX] is down 0.23% over the past day.
